Clinical hold disclosureFiled September 10, 2026
Yarrow Bioscience, Inc.: SEC 8-K mentions a clinical hold
Yarrow Bioscience, Inc. filed an 8-K with the SEC on September 10, 2026 that mentions a clinical hold, a complete response letter and topline results. A mention is not always a hold in effect: the filing has the passage.
On the record
- Filer
- Yarrow Bioscience, Inc.
- Filed
- 2026-09-10
- Form
- 8-K
- Mentions
- clinical hold, complete response letter, topline results
- Source
- SEC EDGAR ↗
The full record
An account shows the passage of the filing that mentions the hold.
What a clinical hold disclosure is
A clinical hold is an FDA order to delay a proposed clinical investigation or to suspend one that is under way. FDA does not publish holds; a listed company discloses one in an 8-K filed with the SEC. A filing can also mention a hold that has been lifted, or one that is only a risk, so the filing itself is the record.
More
Watch Yarrow Bioscience, Inc
A free account shows the last 7 days of every FDA, SEC and ClinicalTrials.gov source. Pro adds a watchlist: one email when FDA acts on a company you name.
From SEC EDGAR. The record may have changed since it was read.
Approve Suite is not affiliated with FDA or the SEC, or with Yarrow Bioscience, Inc. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.